ACCP is pleased to offer satellite symposia as a forum for the presentation of industry-sponsored educational programs during the International Congress. Acceptable educational formats for satellite symposia include presentations by speakers, panel discussions, films, and video presentations. Attendance at a satellite symposium will range from 75 to 200 attendees, depending on the topic and concurrent symposia. The following programs are available for continuing pharmacy education credit, and there is no fee to attend.
Monday, April 27
Rationale for Use of Incretin-Based Therapy in Type 2 Diabetes
Registration and Lunch
11:00 a.m. – 12:00 p.m.
Satellite Symposium
12:00 p.m. – 2:00 p.m.
Location:
Rosen Centre Hotel
Junior Ballroom F (located on the first level of the Rosen Centre)
Program Overview:
Despite the wide availability of antidiabetes therapies, less than half of adults in the United States with type 2 diabetes achieve ADA recommended A1C levels of <7%. Reasons for this include failure to address the progressive nature of diabetes, loss of therapy’s efficacy over time, undesirable side effects, and clinical inertia.
Recently, new insight into the pathophysiology of type 2 diabetes has led to development of a distinct class of hypoglycemic agents that target the incretin pathway. he pharmacologic basis of incretin therapies evolved from the observation that an oral glucose load more effectively triggers insulin release than the same amount of glucose given intravenously.
Because the incretin pathway is attenuated in type 2 diabetes, pharmacologic agents that mimic the effect of incretins or block the inactivation of incretin hormones by DDP-4 offer a welcome new option for the treatment of diabetes. Results from clinical studies suggest that incretin mimetics and DPP-4 inhibitors are safe and effective in improving glycemia, with significant reductions in postprandial glycemia and favorable (GLP-1 analogs) or neutral (DPP-4 inhibitors) effects on weight.
The potentially devastating consequences of uncontrolled diabetes underscore the need to treat with the most effective agents for maintaining glycemic control.
Educational Objectives:
At the conclusion of this activity, participants should be able to:
- Explain the issues preventing patients from achieving established treatment goals.
- Review the safety and efficacy data from recent clinical trials for various incretin therapies.
- Discuss how to identify appropriate candidates for incretin therapy and how to incorporate this therapy into treatment algorithms for diabetes.
Target Audience:
The target audience for this educational activity is pharmacists caring for patients with type 2 diabetes.
Agenda & Faculty:
Welcome, Introduction, and Program Overview
Challenges in Meeting Established Goals
Stuart T. Haines, Pharm.D., FCCP, BCPS, BC-ADM
Professor and Pharmacotherapy Specialist
University of Maryland School of Pharmacy
Baltimore, Maryland, USA
Clinical Pharmacy Specialist
West Palm Beach VA Medical Center
West Palm Beach, Florida, USA
Evidence for Use of Incretin-Based Therapy
Richard E. Pratley, M.D.
Professor of Medicine
University of Vermont College of Medicine
University of Vermont
Burlington, Vermont, USA
Integrating Incretin Therapy into Everyday Clinical Practice
Susan Cornell, Pharm.D., CDE, CDM
Assistant Professor
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois, USA
Panel Discussion/Question & Answer Session
Continuing Education Credit:
2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit.
This program is supported by an independent educational grant from Novo Nordisk Inc.
Registration Information:
ONLINE: Register online at www.schererclin.com/ACCP09.
PHONE: Call Peter Macholdt at (609) 466-6458, between the hours of 9:30 a.m. and 4:30 p.m. Eastern time, Monday through Friday. Messages can be left after hours.